Arrowhead Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 3, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Market Capitalization	9,080	4,769	2,408	2,880	3,498	6,509
Market Cap Growth	276.80%	98.03%	-16.40%	-17.67%	-46.25%	47.77%
Enterprise Value	9,094	4,588	2,436	2,799	3,183	6,017
Last Close Price	64.33	34.49	19.37	26.87	33.05	62.43
PE Ratio	43.78	-	-	-	-	-
PS Ratio	8.53	5.75	678.12	11.96	14.38	47.07
PB Ratio	15.55	9.47	12.60	10.03	8.36	15.92
P/TBV Ratio	16.57	10.39	13.61	11.03	9.05	16.47
P/FCF Ratio	28.91	30.40	-	-	-	44.06
P/OCF Ratio	27.44	26.56	-	-	-	37.99
EV/Sales Ratio	8.34	5.53	686.02	11.63	13.09	43.51
EV/EBITDA Ratio	27.93	37.52	-	-	-	-
EV/EBIT Ratio	30.26	46.65	-	-	-	-
EV/FCF Ratio	28.24	29.25	-	-	-	40.72
Debt / Equity Ratio	1.24	1.48	4.46	1.34	0.20	0.06
Debt / EBITDA Ratio	2.04	5.36	-	-	-	-
Debt / FCF Ratio	2.17	4.74	-	-	-	0.17
Net Debt / Equity Ratio	-0.38	-0.34	0.91	-0.04	-0.69	-0.84
Net Debt / EBITDA Ratio	-0.66	-1.42	-0.30	0.06	1.71	2.43
Net Debt / FCF Ratio	-0.67	-1.11	-0.29	0.04	1.52	-2.32
Asset Turnover	0.83	0.66	0.00	0.33	0.35	0.22
Quick Ratio	3.26	4.73	6.57	3.75	2.67	2.58
Current Ratio	3.38	4.86	6.74	3.95	2.92	2.63
Return on Equity (ROE)	75.50%	8.67%	-254.98%	-59.33%	-42.68%	-32.36%
Return on Assets (ROA)	14.35%	4.87%	-39.43%	-17.58%	-15.91%	-15.11%
Return on Invested Capital (ROIC)	81.47%	16.53%	-187.71%	-101.05%	-180.86%	-127.38%
Return on Capital Employed (ROCE)	23.90%	8.30%	-58.00%	-31.10%	-32.30%	-26.40%
Earnings Yield	2.17%	-0.03%	-24.90%	-7.13%	-5.03%	-2.16%
FCF Yield	3.46%	3.29%	-25.10%	-11.48%	-5.40%	2.27%
Buyback Yield / Dilution	-10.94%	-11.67%	-12.21%	-1.26%	-1.62%	-3.00%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q